Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study

Bo Noordman; Manon Spaander; R. Valkema; Bas Wijnhoven; MIV Henegouwen; J (Joël) Shapiro; Katharina Biermann; Ate van der Gaast; R van Hillegersberg; M Hulshof; KK Krishnadath; Sjoerd Lagarde; GAP Nieuwenhuijzen; LE Oostenbrug; PD (Peter) Siersema; EJ Schoon; MN Sosef; Ewout Steyerberg; Jan van Lanschot

doi:10.1016/s1470-2045(18)30201-8

Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study

Bo Noordman, Manon Spaander, R. Valkema, Bas Wijnhoven, MIV Henegouwen, J (Joël) Shapiro, Katharina Biermann, Ate van der Gaast, R van Hillegersberg, M Hulshof, KK Krishnadath, Sjoerd Lagarde, GAP Nieuwenhuijzen, LE Oostenbrug, PD (Peter) Siersema, EJ Schoon, MN Sosef, Ewout Steyerberg, Jan van Lanschot

Research output: Contribution to journal › Article › Academic › peer-review

133 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	965-974
Number of pages	10
Journal	Lancet Oncology
Volume	19
Issue number	7
DOIs	https://doi.org/10.1016/s1470-2045(18)30201-8
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/s1470-2045(18)30201-8

http://hdl.handle.net/1765/108901

Cite this

Noordman, B., Spaander, M., Valkema, R., Wijnhoven, B., Henegouwen, MIV., Shapiro, J., Biermann, K., van der Gaast, A., van Hillegersberg, R., Hulshof, M., Krishnadath, KK., Lagarde, S., Nieuwenhuijzen, GAP., Oostenbrug, LE., Siersema, PD., Schoon, EJ., Sosef, MN., Steyerberg, E., & van Lanschot, J. (2018). Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncology, 19(7), 965-974. https://doi.org/10.1016/s1470-2045(18)30201-8

@article{3b02899443dc44088d35cafe1411a062,

title = "Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study",

author = "Bo Noordman and Manon Spaander and R. Valkema and Bas Wijnhoven and MIV Henegouwen and Shapiro, {J (Jo{\"e}l)} and Katharina Biermann and {van der Gaast}, Ate and {van Hillegersberg}, R and M Hulshof and KK Krishnadath and Sjoerd Lagarde and GAP Nieuwenhuijzen and LE Oostenbrug and Siersema, {PD (Peter)} and EJ Schoon and MN Sosef and Ewout Steyerberg and {van Lanschot}, Jan",

year = "2018",

doi = "10.1016/s1470-2045(18)30201-8",

language = "Undefined/Unknown",

volume = "19",

pages = "965--974",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "7",

}

Noordman, B , Spaander, M , Valkema, R , Wijnhoven, B, Henegouwen, MIV, Shapiro, J, Biermann, K, van der Gaast, A, van Hillegersberg, R, Hulshof, M, Krishnadath, KK, Lagarde, S, Nieuwenhuijzen, GAP, Oostenbrug, LE, Siersema, PD, Schoon, EJ, Sosef, MN, Steyerberg, E & van Lanschot, J 2018, 'Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study', Lancet Oncology, vol. 19, no. 7, pp. 965-974. https://doi.org/10.1016/s1470-2045(18)30201-8

TY - JOUR

T1 - Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study

AU - Noordman, Bo

AU - Spaander, Manon

AU - Valkema, R.

AU - Wijnhoven, Bas

AU - Henegouwen, MIV

AU - Shapiro, J (Joël)

AU - Biermann, Katharina

AU - van der Gaast, Ate

AU - van Hillegersberg, R

AU - Hulshof, M

AU - Krishnadath, KK

AU - Lagarde, Sjoerd

AU - Nieuwenhuijzen, GAP

AU - Oostenbrug, LE

AU - Siersema, PD (Peter)

AU - Schoon, EJ

AU - Sosef, MN

AU - Steyerberg, Ewout

AU - van Lanschot, Jan

PY - 2018

Y1 - 2018

U2 - 10.1016/s1470-2045(18)30201-8

DO - 10.1016/s1470-2045(18)30201-8

M3 - Article

VL - 19

SP - 965

EP - 974

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 7

ER -